• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Why Tandem Diabetes Care Stock Is Cratering Today

cafead

Administrator
Staff member
  • cafead   Aug 04, 2022 at 06:32: PM
via
  • Tandem Diabetes Care released its second-quarter 2022 results after the closing bell on Wednesday.
  • The company's Q2 numbers failed to live up to expectations, and lowering its full-year guidance didn't help matters.

article source